March 14, 2019
Targovax grants Zelluna Immunotherapy an FTO license to intellectual property relating to mutant RAS T cell receptor technology
Media
March 13, 2019
BONESUPPORT™ launching a new product – BONIFY™ – US product portfolio expansion
March 11, 2019
Strongbridge Biopharma plc Announces Top-Line Results from Extended Evaluation Phase of the Pivotal Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Potential Treatment of Endogenous Cushing’s Syndrome
March 11, 2019
Modus Therapeutics strengthens management team with appointment of Mats Blom, MBA as CFO
March 04, 2019
Strongbridge Biopharma plc Announces Upcoming Presentation of New Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2019 Annual Meeting of the Endocrine Society (ENDO)
March 04, 2019
Fusion Pharmaceuticals Announces Appointment Of John J. Crowley As Chief Financial Officer
February 27, 2019
Aprea Therapeutics Adds New Investor to Series C Financing
February 27, 2019
BONESUPPORT HOLDING AB (publ) – Full Year Report 2018
February 27, 2019
Nordic Nanovector ASA – Results for the Fourth Quarter and Full Year 2018
February 27, 2019
Data from Oncopeptides Clinical Trials HORIZON and ANCHOR Evaluating Melflufen in RRMM Selected for Presentation at the AACR Annual Meeting
